Diater, S.A.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Diater, S.A. - overview
Established
1999
Location
Leganes, -, Spain
Primary Industry
Biotechnology
About
Based in Spain, Diater, S. A. specializes in diagnostic and therapeutic products aimed at allergy-related conditions, providing healthcare professionals with innovative tools to enhance patient care. Diater, S.
A. operates as a pharmaceutical laboratory focused on developing and manufacturing allergy diagnosis and treatment products. Founded in 1999 in Leganes, Spain, the company has conducted a total of 3 deals with its most recent funding round being a Buyout in November 2023, amounting to EUR 45. 00 mn from Nazca Capital.
The company has seen steady growth and has no known subsidiaries or parent companies. Diater Laboratorio Farmacéutico specializes in developing and manufacturing diagnostic tools and therapeutic products targeting allergy-related conditions. Their offerings include a comprehensive range of allergy diagnosis tools and treatments designed for patients suffering from various allergic reactions. These products are subjected to rigorous quality controls to ensure reliability and consistency.
Diater primarily serves healthcare professionals, including allergists and general practitioners, who rely on these products to improve patient outcomes. The company distributes its products across various geographical markets, focusing on both domestic and international sales to meet the demand for innovative allergy solutions. For the most recent fiscal year 2023, Diater reported a revenue of EUR 24,942,384. 40 and an EBITDA of EUR -3,503,969.
40. The revenue is generated through direct sales to healthcare providers and institutions that implement its diagnostic and therapeutic products. Sales channels include direct purchases from hospitals, clinics, and pharmacies, with potential subscription models for ongoing supply agreements tailored to specific product needs. In November 2023, Worg, a portfolio company of various investors, agreed to acquire a majority stake in Diater, S.
A. from Nazca Capital, which will enhance the company’s growth through Worg's structural and financial support. As part of its future growth strategy, Diater aims to expand its product line and enter new markets. Specific plans include launching new allergy diagnostics and treatment solutions in response to increasing global demand, with targeted expansions into regions with significant healthcare needs.
The recent funding will facilitate these initiatives, allowing for enhanced product development and market penetration.
Current Investors
Nazca Capital, Worg
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Diagnostic, Medical & Imaging Laboratories
Website
www.diater.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Diater, S.A. - timeline of key events
Diater, S.A. - financials
| Fiscal Year Ended | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 10,502,984 | 12,123,279 | 14,273,386 | 15,268,574 | 17,998,335 | 16,394,612 | 16,779,309 | - | - | - |
| % Revenue Growth (YoY) | - | 15.4% | 17.7% | 7.0% | 17.9% | (8.9%) | 2.3% | - | - | - |
| EBITDA (USD) | 1,683,637 | 3,027,377 | 3,393,157 | 4,555,583 | 6,132,056 | 5,806,680 | 5,974,244 | - | - | - |
| Operating Income (USD) | 951,346 | 2,347,133 | 2,748,429 | 3,889,603 | 5,629,673 | 5,251,509 | 5,340,479 | - | - | - |
| Operating Margin | 9.1% | 19.4% | 19.3% | 25.5% | 31.3% | 32.0% | 31.8% | - | - | - |
| % EBITDA Margin | 16.0% | 25.0% | 23.8% | 29.8% | 34.1% | 35.4% | 35.6% | - | - | - |
| NET Income (USD) | 715,361 | 1,808,495 | 1,875,467 | 3,025,190 | 4,379,704 | 3,848,698 | 4,775,491 | - | - | - |
| % Net Margin | 6.8% | 14.9% | 13.1% | 19.8% | 24.3% | 23.5% | 28.5% | - | - | - |
Diater, S.A. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Debt | Completed | Diater, S.A. | - | ||||||||
| Buyout | Completed | Diater, S.A. | - |
Displaying 1 - 2 of 2
Diater, S.A. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.